Application of multiple techniques at different conditions presents a more complete picture of a dynamic situation.
Advanced therapy medicinal products pose unique manufacturing challenges that will require appropriate and thoughtful facility design and equipment.
Dirk Margosch, Vice President Visual Inspection, Assembly & Secondary Packaging at Vetter Pharma-Fertigung GmbH & Co KG, provides advice on final product inspection for small batch sizes. He also discusses how to maintain cold chain during visual inspection.
The authors present the CMO's perspective on various potential sources of sponsor-CMO conflicts.
Bio-Rad Laboratories, Inc., Pioneer™ Antibody Discovery Platform helps streamline the phage display-based discovery process and provides researchers with superior identification of high-quality therapeutic antibodies.
This research proposes a method for separating and purifying tissue-type plasminogen activator from a fungal cell source.
This research proposes a method for separating and purifying tissue-type plasminogen activator from a fungal cell source.
This research proposes a method for separating and purifying tissue-type plasminogen activator from a fungal cell source.
This research proposes a method for separating and purifying tissue-type plasminogen activator from a fungal cell source.
This research proposes a method for separating and purifying tissue-type plasminogen activator from a fungal cell source.
Unprocessed bulk material harvested directly from the bioreactor should be tested for contamination prior to downstream processing.
The authors present a risk analysis of the impact of various business and operating risks on three facility layout strategies.
Mock inspections-if conducted properly-can prepare a pharma company for the day FDA knocks on the door.
Fluorescence has long been used to detect biological targets. As these measurements are becoming more and more quantitative, standards are needed to ensure accuracy and reproducibility.
Fluorescence has long been used to detect biological targets. As these measurements are becoming more and more quantitative, standards are needed to ensure accuracy and reproducibility.
Determining a peptide’s purity is challenging because impurities are often structurally similar to each other and the API and can be present at very low concentrations. New approaches offer a solution.
The authors give special consideration factors affecting blow–fill–seal technology.
Kinetic models can be used to study aggregation and fragmentation to help ensure stability.
A key technology that can help achieve a continuous production flow is single-pass tangential flow filtration.
A key technology that can help achieve a continuous production flow is single-pass tangential flow filtration.
A key technology that can help achieve a continuous production flow is single-pass tangential flow filtration.
Download the White Paper and learn how detailed characterization can guide successful development of gene therapy products.
The authors discuss an alternative to traditional Protein A resins.